The Bristol-Myers Squibb Research and Development (R&D) organization is one of the world's most innovative, productive, and respected scientific research organizations. Their purpose is: to discover and develop innovative, cost-effective medicines which address significant unmet medical needs and enhance and extend human life. Moreover, R&D is an extraordinary area in which to work—there are 6,500 employees’ remarkable talent, dedication, and passion for using science to improve human health.
In less than four years, R&D has delivered eight new drugs. By industry standards, this places Bristol-Myers Squibb among the most productive pharmaceutical companies in the world today. New products include treatments for several major disease areas, including cancer, psychiatric disorders, HIV/AIDS, hepatitis B, and rheumatoid arthritis.
In addition, their research and development activities—centered in four major U.S. facilities and numerous other facilities in the U.S. and worldwide—are creating and sustaining an outstanding pipeline. Compounds with exciting potential are progressing through discovery, exploratory development, and full development expeditiously. They are working to discover and develop treatments specifically for: Cancer, atherosclerosis/thrombosis ,diabetes, obesity,psychiatric disorders , Alzheimer’s disease , hepatitis , HIV/AIDS , rheumatoid arthritis and solid organ transplant rejection.
To achieve ambitious goals in these areas, they are aggressively leveraging a broad range of strategies and tools. For example, their scientists are pioneering the use of genomics and pharmacogenomics to discover and characterize new compounds. In addition, they have created alliances with other research organizations in order to respond swiftly to new opportunities and thereby increase their success rate. Moreover, they recognize that gaining approval from the FDA or other health agencies around the globe does not mark the end of their development work. They are committed to unlocking the full value of the products they discover and develop.
Bristol-Myers Squibb has consolidated its patient assistance programs in the U.S. into a single LifeLines of Care initiative that continues to provide assistance for qualifying patients with financial hardships. In 2006, approximately 570,000 patients in the U.S. benefited, with donated products valued at more than $418 million at wholesale list price.
Selected Key Products:
Abilify® (aripiprazole)Atripla™ (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg)
Injection Videx® EC (didanosine, delayed-release capsules)Zerit® (stavudine)
Bristol-Myers Squibb in China
Set up a clinic research center in China (They have four R&D centers all over the world and set up clinic research centers in 14 countries)
Sino-American Shanghai Squibb Pharmaceuticals Ltd (SASS)--found in 1982 by joint venture of Bristol-Myers Squibb Company USA, Shanghai Pharmaceutical Group CO. Ltd. and China National Pharmaceutical Foreign Trade Corporation. The company is the first Sino-American Joint Venture pharmaceuticals company in China. It is also the only production base overseas except its headquarters
Bristol-Myers Squibb(China) Investment Ltd. in 1995
Mead Johnson (Guangzhou) Ltd. in1997
Bristol-Myers Squibb(Shanghai) Trade Ltd. in 1997